Novastra reported further Phase 1 data for OAP-101 at SITC 2026. Findings from three heavily pretreated patients with advanced melanoma reinforced feasibility and showed a consistent innate-to-Th1 pharmacodynamic signature. OAP-101 is investigational; larger cohorts and formal response assessment are needed to evaluate clinical activity.

Novastra established a Scientific Advisory Board and appointed senior advisors to guide and support the scientific validation and clinical development of programs based on its proprietary OmniAntigen™ Platform (OAP).

Novastra will present first-in-human data from an ongoing investigator-initiated Phase 1 study of OAP-101 in anti-PD-1-refractory advanced melanoma at the SITC 2026 Annual Meeting. The poster will focus on feasibility and innate-to-Th1 pharmacodynamics.

Novastra reported initial data from an ongoing investigator-initiated Phase 1 study of OAP-101 in heavily pretreated, anti-PD-1-refractory advanced melanoma. Interim findings from three patients showed feasible repeat dosing and immune activation consistent with the platform’s proposed mechanism. OAP-101 is investigational, and these early findings require further evaluation.

Novastra will present initial clinical data from an ongoing investigator-initiated Phase 1 study of OAP-101 in anti-PD-1-refractory advanced melanoma at ESMO Congress 2026.

Novastra appointed Sarah Guadagno, PhD, as Head of Medical Affairs as Novastra advances OAP-101 toward global clinical development and builds the medical strategy to support its broader pipeline.

Novastra appointed Jarett Poll as Chief Financial Officer as Novastra drives its lead programs toward global clinical and operational development.

Early investigator-assessed observations included immune activation and initial safety and tumor-behavior readouts within the OAP-101 treatment window in a heavily pretreated, checkpoint-refractory population. OAP-101 is investigational. These interim observations are from an early-stage study and do not establish safety or efficacy.

This capital powers the OmniAntigen™ Platform and its pipeline of XIRT™ immune-priming programs.

The milestone opened human evaluation of OAP-101 in advanced, checkpoint-refractory melanoma.